Cytokinetics’ stock rockets to 19-year high after positive data on heart-disease treatment

Cytokinetics’ stock rocketed Wednesday, after the cardiovascular-biopharmaceutical company announced positive results from a Phase 3 trial of aficamten, a treatment for hypertrophic cardiomyopathy.

Previous post 11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria
Next post A record share of S&P 500 stocks have underperformed the index in 2023 as ‘weirdest bull market in decades’ marches on